Summit Securities Group’s Moderna MRNA Stock Holding History

Summit Securities Group’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,000	Closed	-$129K	–	1160
2025 Q3	$129K	Buy	+5,000	New	+$139K	0.03%	340
2023 Q4	–	Sell	-1,000	Closed	-$103K	–	819
2023 Q3	$103K	Hold	1,000	–	–	0.01%	220
2023 Q2	$122K	Buy	+1,000	New	+$133K	0.02%	266
2021 Q3	–	Sell	-10	Closed	-$235K	–	822
2021 Q2	$235K	Buy	+10	New	+$1.79K	0.02%	613
2021 Q1	–	Sell	-185	Closed	-$1.93M	–	705
2020 Q4	$1.93M	Buy	+185	New	+$18.7K	0.16%	148

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Summit Securities Group's MRNA Position: Q1 2026 in Review

Summit Securities Group increased its Moderna (MRNA) stake by 215% in Q1 2026, buying an estimated $51.7K and bringing the position to 1,626 shares worth $82.6K. The position accounts for 0.01% of the portfolio, ranked #311.

Summit Securities Group first reported a position in MRNA in Q4 2020 and has held it in 11 quarters since. The position peaked at $1.27M in Q4 2020. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

Summit Securities Group held 1,626 shares of Moderna worth $82.6K as of Q1 2026.
Summit Securities Group bought 1,109 Moderna shares in Q1 2026, an estimated $51.7K.
Moderna made up 0.01% of Summit Securities Group's portfolio in Q1 2026, its #311 holding.
Summit Securities Group first reported a position in Moderna in Q4 2020 and has held it in 11 quarters since.
Summit Securities Group's Moderna position peaked at $1.27M in Q4 2020.
722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.